Ana-Maria Henao-Restrepo

Publications (5)26.76 Total impact

• Article: Comparing pneumococcal conjugate vaccine schedules in infancy.

  Nicola Low, Pippa Scott, Ana Maria Henao Restrepo
  Vaccine 02/2012; · 3.77 Impact Factor
• Source

  Available from: Nicola Low

  Article: Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis.

  Nicola Low, Sibylle Kraemer, Martin Schneider, Ana Maria Henao Restrepo
  [show abstract] [hide abstract]
  ABSTRACT: Aerosols are the most promising non-injectable method of measles vaccination studied so far and their efficacy is thought to be comparable to injected vaccine. We conducted a systematic review up to May 2006 to examine the immunogenicity and safety of aerosolized measles vaccine (Edmonston-Zagreb or Schwarz strains) 1 month or more after vaccination. Where possible we estimated pooled serological response rates and odds ratios (with 95% confidence intervals, CI) comparing aerosolized and subcutaneous vaccines in children in three age groups and adults. We included seven randomized trials, four non-randomized trials and six uncontrolled studies providing serological outcome data on 2887 individuals. In children below 10 months, the studies were heterogeneous. In four comparative studies, seroconversion rates were lower with aerosolized than with subcutaneous vaccine and in two of these the difference was unlikely to be due to chance. In children 10-36 months, the pooled seroconversion rate with aerosolized vaccine was 93.5% (89.4-97.7%) and 97.1% (92.4-100%) with subcutaneous vaccine (odds ratio 0.27, 0.04-1.62). In 5-15-year olds the studies were heterogeneous. In all comparative studies aerosolized vaccine was more immunogenic than subcutaneous. Reported side effects were mild. Aerosolized measles vaccine appears to be equally or more immunogenic than subcutaneous vaccine in children aged 10 months and older. Large randomized trials are needed to establish the efficacy and safety of aerosolized measles vaccine as primary and booster doses.
  Vaccine 02/2008; 26(3):383-98. · 3.77 Impact Factor
• Article: Global measles elimination efforts: the significance of measles elimination in the United States.

  Peter M Strebel, Ana-Maria Henao-Restrepo, Edward Hoekstra, Jean-Marc Olive, Mark J Papania, Stephen L Cochi
  [show abstract] [hide abstract]
  ABSTRACT: Lessons learned from the successful end of endemic measles virus transmission (i.e., elimination) in the United States include the critical roles of strong political commitment, a regionwide initiative, adequate funding, and a broad coalition of partners. Implications of measles elimination in the United States for global measles control and regional elimination efforts include demonstration of the high vaccination coverage and, in turn, population immunity needed for elimination; the importance of accurate monitoring of vaccination coverage at local, state, and national levels; a vaccination strategy that includes at least 2 opportunities for measles immunization; and the essential role of integrated epidemiological and laboratory surveillance. The United States, with a population of 288 million, is, to our knowledge, the largest country to have ended endemic measles transmission. This experience provides evidence that sustained interruption of transmission can be achieved in large geographic areas, suggesting the feasibility of global eradication of measles.
  The Journal of Infectious Diseases 06/2004; 189 Suppl 1:S251-7. · 6.41 Impact Factor
• Article: Experience in global measles control, 1990-2001.

  Ana-Maria Henao-Restrepo, Peter Strebel, Edward John Hoekstra, Maureen Birmingham, Julian Bilous
  [show abstract] [hide abstract]
  ABSTRACT: Worldwide during the 1980s remarkable progress was made in controlling measles through increasing routine measles vaccination to nearly 80%. In 2000, an estimated 777,000 measles deaths occurred, of which 452,000 were in the African Region of the World Health Organization (WHO). In 2001, WHO and the United Nations Children's Fund published a 5-year strategic plan to reduce measles mortality by half by 2005. Strategies include providing a second opportunity for measles immunization to all children through nationwide supplementary immunization activities, increasing routine vaccination coverage, and improving surveillance with laboratory confirmation of suspected measles cases. In 2000, over 100 million children received a dose of measles vaccine through supplementary immunization activities, a number projected to increase during 2002-2005. Current systems for monitoring measles vaccination coverage and disease burden must be improved to accurately assess progress toward measles control goals.
  The Journal of Infectious Diseases 06/2003; 187 Suppl 1:S15-21. · 6.41 Impact Factor
• Article: Determining measles-containing vaccine demand and supply: an imperative to support measles mortality reduction efforts.

  Alejandro Costa, Ana-Maria Henao-Restrepo, Shanelle Marie Hall, Stephen Jarrett, Edward John Hoekstra
  [show abstract] [hide abstract]
  ABSTRACT: Measles remains a major cause of mortality with an estimated 745,000 deaths in 2001. The timely, sustained, and uninterrupted supply of affordable vaccines is critical for global efforts to reduce measles mortality. The measles vaccine supply needs to be considered in the context of vaccine security. In 2000, the World Health Organization (WHO) and United Nations Children's Fund (UNICEF) issued a number of new recommendations for measles control that resulted in a two-fold increase in the number of measles-containing vaccine (MCV) doses administered between 2000 and 2002. Any additional increments in mass campaigns must be duly planned and have time lines so that vaccine production capacities are increased to optimal levels. The cornerstone of vaccine security efforts remains at the country level. WHO and UNICEF, with major partners, will review progress on measles mortality reduction and assess the feasibility of global measles eradication. Strong collaboration by all key stakeholders will be invaluable.
  The Journal of Infectious Diseases 06/2003; 187 Suppl 1:S22-8. · 6.41 Impact Factor